July 30, 2026- Teleflex Incorporated announced it has received Biologics License Application (BLA) approval for EZPLAZ™ Freeze Dried Plasma (FDP) from the U.S. Food and Drug Administration (FDA). EZPLAZ™ FDP is approved for transfusion in adults with bleeding-related conditions requiring replacement of plasma coagulation factors, including uncontrolled bleeding (hemorrhage), when plasma is required and other plasma products are not available. This landmark approval is the first freeze dried plasma licensed by the FDA, and the first biologics license for a blood component for Teleflex.
Based on this clinical challenge, the Defense Health Agency (DHA) has made the development of an FDA-approved, commercially available source of freeze dried plasma a top priority. In April 2014, Vascular Solutions LLC (a wholly owned subsidiary of Teleflex) entered a Cooperative Research and Development Agreement (CRADA) with the team now known as Warfighter Protection and Acute Care (WPAC), which is part of DHA.